You built the instrument. We’ll build the business that sells it.
For technical founders and C-level teams, pre-seed to Series B, with small, limited, or no commercial team.
Focus on the science, we’ll take it to market.
35+ years and 25+ launches, working from day one. No twelve-month build, no equity grant, no bad hire to unwind.
30,000+ scientists and KOLs across flow cytometry, bioprocess, and metabolic research. The people who decide whether your category adopts.
CDMO and supply chain networks across the Americas, EU, and Asia, so making the units is never the thing that stalls the launch.
Companies we’ve worked with have raised $150M+. At pre-seed to Series B, commercial traction is what the term sheet is built on.
Sartorius acquired IntelliCyt in June 2016 to anchor its position in immuno-oncology and antibody discovery. In the four years into the deal, we scaled the iQue platform from a niche high-throughput screening tool into a system installed at the top 15 global pharmaceutical companies, and delivered a cash exit at a multiple well above life-science tools norms.
Led by Janette Phi, Chief Commercial Officer, then Chief Business Officer
ThinkCyte had breakthrough science, Ghost Cytometry published in Science, but no product and no go-to-market organization. We built the five-year roadmap across instruments, consumables, reagents, and cloud AI software, took VisionSort from design to manufacturing release in nine months, launched at SLAS 2023, and stood up a 30-person global commercial organization in the first year.
Led by Janette Phi, Chief Business and Commercial Officer
Scaling a hardware-plus-AI platform out of Japan into US and EU markets needed capital that pure venture equity could not efficiently supply. We closed a $24M round in November 2023 and a $32M Series C in August 2024, blending institutional venture, strategic corporate investors, and Japanese government non-dilutive funding (NEDO Deep Tech Startup Program), bringing total funding to $91M while limiting dilution.
Led by Janette Phi, Chief Business Officer
ForteBio entered a market defined by Biacore’s expensive, low-throughput SPR systems. Positioning Bio-Layer Interferometry as the faster, higher-throughput alternative, we launched the Octet QK (2005) and Octet RED (2008) alongside a biosensor consumables line that reached 11 products, establishing the recurring-revenue model. The platform became the anchor asset in Pall’s acquisition of ForteBio, today part of Sartorius.
Led by Janette Phi, VP Marketing
No handoffs between specialists. No disappearing between phases.
Define the market, the buyer, the commercial model, and the milestone-based roadmap. Translate your science into the right path to revenue.
Launch planning, pricing, reimbursement, channel strategy, and field readiness. Everything that turns a cleared product into commercial scale.
Identify, evaluate, and negotiate partnerships, licensing deals, and collaborations that expand capabilities and unlock strategic growth.
Global manufacturing networks, CMO/CDMO selection, scale-up readiness, and distribution partnerships across the Americas, EU, and Asia.
Microbioreactors and nanoparticle analysis platforms we have commercialized for the technology developers behind them.
Accelerate Cell Line Development by 29 to 42 percent with true dynamic mixing at 24- and 96-well scale. Real-time DO and pH metabolic insight at the microplate stage.
Request DetailsSee metabolism in motion. Continuously monitor DO, pH, OCR, and ECAR in real time for full-course metabolic profiling throughout the entire culture period.
Request DetailsThree founders with decades of senior leadership across pharma, biotech, and diagnostics, backed by specialists across every commercial function and an advisory board of industry-leading experts.
Strategy, commercialization, and capital. Multi-product launches across pharma and life science tools.
Operations, manufacturing, and global distribution. Decades scaling life science companies through launch and beyond.
Licensing, partnerships, and business development across biotech, diagnostics, and life science tools.
A 12-point self-assessment built from 20+ life science launches. Use it to evaluate whether your product is ready for commercial launch.